- Home
- SSAC vs TNXP Comparison
SSAC vs TNXP Comparison
Compare SSAC & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSAC | TNXP |
|---|---|---|
| Founded | 2025 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.9M | 199.7M |
| IPO Year | 2025 | 2008 |
Fundamental Metrics
Financial Performance| Metric | SSAC | TNXP |
|---|---|---|
| Price | $10.09 | $12.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.4K | ★ 435.4K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $9.85 | $9.40 |
| 52 Week High | $10.10 | $29.19 |
Technical Indicators
Market Signals| Indicator | SSAC | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 59.23 | 51.36 |
| Support Level | $10.05 | $11.98 |
| Resistance Level | N/A | $13.18 |
| Average True Range (ATR) | 0.02 | 0.68 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 80.00 | 28.00 |
Price Performance
Historical ComparisonAbout SSAC SPACSphere Acquisition Corp. Class A Ordinary Shares
SPACSphere Acquisition Corp is a blank check company.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.